Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations
(MedPage Today) -- Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized UNICORN trial from Japan... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 22, 2023 Category: Hematology Source Type: news
AI Could Predict a Nonsmoker's Risk for Lung Cancer
WEDNESDAY, Nov. 22, 2023 -- Artificial intelligence (AI) can help assess lung cancer risk in nonsmokers, a new study shows.The “CXR-Lung-Risk” AI program evaluates routine chest X-ray images, looking for patterns associated with lung cancer,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 22, 2023 Category: General Medicine Source Type: news
AI model identifies high-risk lung cancer in nonsmokers
In this study, the researchers externally validated the model in a separate group of never-smokers who underwent routine outpatient chest x-rays from 2013 to 2014. The primary outcome was six-year incident lung cancer, identified using International Classification of Disease codes. Risk scores were then converted to low, moderate, and high-risk groups based on externally derived risk thresholds.
Of 17,407 patients (mean age 63 years) included in the study, 28% were deemed high risk by the deep learning model, and 2.9% of these patients later had a diagnosis of lung cancer, according to the findings. In addition, the high-...
Source: AuntMinnie.com Headlines - November 22, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Source Type: news
USPSTF-recommended screening leads to less cancer burden
Increasing use of recommended screening strategies could reduce the U.S. cancer burden, according to research published November 22 in JAMA Network Open.
A team led by Amy Knudsen, PhD, from Massachusetts General Hospital in Boston found an increase of 10 percentage points in the uptake of lung, colorectal, breast, and cervical cancer screening at their respective starting ages as recommended by the U.S. Preventive Services Task Force (USPSTF) led to decreased cancer deaths. It highlighted that this could help the U.S. achieve the Cancer Moonshot initiative’s goals.
“Achieving these reductions is predicated on ensuri...
Source: AuntMinnie.com Headlines - November 22, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news
Qure.ai touts AI lung cancer initiative milestone
Qure.ai has processed one million lung scans in an AI lung health initiative that aims to include five million scans.
The initiative is part of a commitment Qure.ai made at the 2022 World Economic Forum’s annual meeting in Davos, at which the biopharmaceutical company AstraZeneca joined the forum's Edison Alliance. The alliance is a partnership between commercial and nonprofit sectors to improve the lives of people through digital inclusion.
Qure.ai is working with AstraZeneca’s A.Catalyst Network for improving patient outcomes, and the Lung Ambition Alliance, a global coalition with the ambition to eliminate lung ca...
Source: AuntMinnie.com Headlines - November 21, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Chest Radiology Source Type: news
Despite decades of promises, health research still overlooks women
With White House initiative, Jill Biden aims to change thatWomen are twice as likely as men to die from heart attacks.When a nonsmoker dies of lung cancer, it ’s twice as likely to be a woman as a man.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 20, 2023 Category: Science Authors: Maggie Fox of the Fuller Project Tags: Medical research Gender Jill Biden Drugs US news Health policy Pharmaceuticals industry Source Type: news
Study Identifies Familial Germline EGFR T790M Variant in Lung Cancer
FRIDAY, Nov. 17, 2023 -- A new familial lung cancer caused by an inherited mutation in EGFR has been described in a study published online Oct. 23 in the Journal of Clinical Oncology.
Geoffrey R. Oxnard, M.D., from the Dana-Farber Cancer Institute... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 17, 2023 Category: Pharmaceuticals Source Type: news
Lunit expands services into Saudi Arabia, secures $150M in funding
Lunit is expanding its services in the Kingdom of Saudi Arabia -- deploying its Lunit Insight CXR in five major hospitals -- and has secured $150 million in funding.Lunit Insight CXR is designed to detect common lung abnormalities, including lung cancer, tuberculosis, and pneumonia. The following hospitals, which in total have over 4,200 beds, will see the technology installed: National Guard Hospital Riyadh, King Abdulaziz Medical City, Security Forces Hospital, Al Takhassusi Hospital, and Al Moosa Specialist Hospital.This partnership builds on Lunit’s successful collaborations in Saudi Arabia, including its participat...
Source: AuntMinnie.com Headlines - November 17, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
ESMO 2023: Tarlatamab Shows Promise for Small Cell Lung Cancer ESMO 2023: Tarlatamab Shows Promise for Small Cell Lung Cancer
"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the L éon Bérard Center in France.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Approves Repotrectinib for ROS1-Positive NSCLC FDA Approves Repotrectinib for ROS1-Positive NSCLC
The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves repotrectinib for ROS1-positive non-small cell lung cancer
On November 15, 2023, the Food and Drug Administration approved repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Osimertinib + Chemo Improves Progression-Free Survival in Advanced NSCLC
THURSDAY, Nov. 16, 2023 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2023 Category: Pharmaceuticals Source Type: news
Road to RSNA 2023: Imaging Informatics Preview
In many respects, AI has come to dominate the field of imaging informatics research, a trend that will be evident at RSNA 2023. In this stop on the Road to RSNA, we take a look at AI as it is being tested in various imaging modalities for communication, analysis, efficiency, organization, and problem-solving. Among them are tests of the effectiveness and accuracy of large language models (LLMs) such as ChatGPT, Bard, and others. We bring you previews of comparison studies of LLMs in generating radiology reports and consumer-friendly health information to support lung cancer prevention, screening, and education. With th...
Source: AuntMinnie.com Headlines - November 16, 2023 Category: Radiology Authors: Liz Carey Tags: 2023 2023 Imaging Informatics Preview Source Type: news
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer
(MedPage Today) -- The FDA approved repotrectinib (Augtyro) -- an oral tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions -- for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2023 Category: American Health Source Type: news
FDA Approves Augtyro (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
